Mitochondrial dysfunction and programmed cell death in osteosarcoma DOI
Ke Zhang, Mingyang Jiang,

Kai-Cheng Liu

et al.

journal of nutritional oncology, Journal Year: 2024, Volume and Issue: 9(2), P. 37 - 45

Published: June 1, 2024

Abstract Osteosarcoma is the most prevalent primary malignant bone tumor, primarily affecting adolescents aged 15–25 years. It characterized by a high recurrence rate, poor prognosis, and lack of important biomarkers. Significant mitochondrial dysfunction in osteosarcoma cells has been widely reported recent studies. Dysfunctional mitochondria occupy an position cellular metabolic reprogramming, immune microenvironment regulation, programmed cell death. Therefore, targeting may represent new mechanism to overcome therapeutic barriers treatment provides crucial target molecules for further development targeted therapies immunotherapies. The present article summarizes reports links it various death mechanisms, aiming provide basis clinical practice.

Language: Английский

FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production DOI Creative Commons
Bo Sun, Peng Ding, Yinghui Song

et al.

Redox Biology, Journal Year: 2024, Volume and Issue: 75, P. 103302 - 103302

Published: Aug. 6, 2024

Mitochondrial dysfunction and metabolic reprogramming can lead to the development progression of hepatocellular carcinoma (HCC). Ferredoxin 1 (FDX1) is a small mitochondrial protein recent studies have shown that FDX1 plays an important role in tumor cuproptosis, but its HCC still elusive. In this study, we aim investigate expression novel functions HCC.

Language: Английский

Citations

16
SLC35A2 is a novel prognostic biomarker and promotes cell proliferation and metastasis via Wnt/β-catenin/EMT signaling pathway in breast cancer DOI Creative Commons

Rushu Yan,

Tianwen Chen

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 2, 2025

Language: Английский

Citations

0
Xanthohumol Regulates Mitophagy in Osteosarcoma Cells via AMPK‐ULK1‐FUNDC1 Signaling Pathway DOI
Qiaofeng Ge,

Zhiliang Yan,

Qian Tian

et al.

Phytotherapy Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

ABSTRACT Osteosarcoma (OS) is the most common primary bone malignancy. The therapeutic efficacy for OS patients has remained stagnant in recent decades. Xanthohumol (XN), a flavonoid naturally found hops, demonstrated significant anticancer properties lung and breast cancer. However, its effect on underlying molecular mechanisms remains uncertain. Therefore, purpose of this study to explore relationship between XN OS. Firstly, we assessed impact cell proliferation migration using CCK‐8, wound‐healing, transwell, clonogenicity assays. Subsequently, examined mitophagy cells through flow cytometry, immunofluorescence, transmission electron microscopy, western blot analysis. Finally, constructed siRNA targeting AMPK validate pathway. In vitro, that inhibited concentration‐ time‐dependent manner. Furthermore, induced mitochondrial damage increased reactive oxygen species (ROS) levels. RNA‐seq analysis suggested potential pathway, which confirmed experimentally by showing reduced ATP levels, altered membrane potential, expression Atg5, Beclin‐1, LC3 proteins. Interestingly, inhibitor Mdivi‐1 reversed caused cells. exerted anti‐OS effects activation AMPK‐ULK1‐FUNDC1 signaling was effectively after knockdown. vivo, subcutaneous nude mouse model without any organ toxicity. emerges as promising pharmaceutical agent

Language: Английский

Citations

0
Integrating network pharmacology and experimental validation to explore the mitophagy‐associated pharmacological mechanism of modified Shisiwei Jianzhong decoction against aplastic anemia DOI
Yun Zhang, Jun Wang, Bo Wang

et al.

Biomedical Chromatography, Journal Year: 2024, Volume and Issue: 38(10)

Published: July 18, 2024

Abstract The aim of this work was to investigate the therapeutic effect modified Shisiwei Jianzhong Decoction (SJD) on aplastic anemia (AA) and its potential pharmacological mechanism from perspective mitophagy. A comprehensive approach combining network pharmacology, mendelian randomization, molecular docking animal experiments applied evaluate properties SJD against AA. By integrating multiple databases, it determined that exerted AA by targeting three key targets [ mammalian target rapamycin ( MTOR), poly(ADP‐ribose) polymerase 1 (PARP1) Sirtuin (SIRT1)] through four core compounds (quercetin, resveratrol, genistein curcumin). Mendelian randomization analysis identified MTOR as a risk factor for occurrence while PARP1 protective factor. Results showed improved peripheral blood counts promoted proliferation hematopoietic stem cells. Mechanistically, SJD, especially at high dose, played role in activating mitophagy‐related proteins PTEN induced kinase (PINK1)/Parkin inhibiting phosphatidylinositol 3‐kinase (PI3K)/protein (AKT)/MTOR pathway. This study revealed first time chemical composition effects AA, which can restore function results provide inspiration clinical application traditional Chinese medicine treatment.

Language: Английский

Citations

1
Identification of a novel mitophagy-related signature for predicting clinical prognosis and immunotherapy of osteosarcoma DOI Creative Commons
Peichuan Xu,

Jiangminghao Zhao,

Wenrui Zhao

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: May 2, 2024

Abstract Background Osteosarcoma (OS) is a highly aggressive malignancy characterized by poor prognosis. Mitochondrial autophagy (mitophagy) has been implicated in tumor initiation, progression, and response to therapy, highlighting it potential prognostic indicator therapeutic target cancers. Despite this, the precise mechanisms underlying mitophagy osteosarcoma remain enigmatic. This research aims develop mitophagy-associated signature guide strategies prognosis estimations. Methods Clinical transcriptome data for patients with skeletal muscle tissue were retrieved from UCSC Xena GTEx. Mitophagy-related genes (MRGs) obtained Kyoto Encyclopedia of Genes Genomes (KEGG) website. A predictive risk model was constructed using Least Absolute Shrinkage Selection Operator (LASSO) algorithm Cox regression analysis. To delve into fundamental gene expression mechanisms, we employed Gene Ontology (GO), KEGG, Set Enrichment Analysis (GSEA). Moreover, different immune-related activities between two groups investigated ascertain efficacy immunotherapy. Lastly, functional analysis key MRAS carried out via vitro experiments pan-cancer small molecule drugs that may screened through molecular docking. Results Based on seven mitophagy-related signatures, stratified high- low-risk categories. The exhibited strong capability, as evidenced Kaplan-Meier analysis, time-dependent AUC, Nomogram. Notably, compared group, individuals high-risk group lower stromal, immune, estimate scores.The infiltration immune cells decreased. Further evidence supporting MRAS's protective role against shown in vitro, where upregulating its could suppress proliferation, migration, invasion while stimulating their apoptosis. Pan-cancer further demonstrated variety tumors. Conclusion study identified elucidated impact cells. Consequently, opened up fresh avenues clinical prediction established basis precision therapy osteosarcoma.

Language: Английский

Citations

0
Mitochondrial dysfunction and programmed cell death in osteosarcoma DOI
Ke Zhang, Mingyang Jiang,

Kai-Cheng Liu

et al.

journal of nutritional oncology, Journal Year: 2024, Volume and Issue: 9(2), P. 37 - 45

Published: June 1, 2024

Abstract Osteosarcoma is the most prevalent primary malignant bone tumor, primarily affecting adolescents aged 15–25 years. It characterized by a high recurrence rate, poor prognosis, and lack of important biomarkers. Significant mitochondrial dysfunction in osteosarcoma cells has been widely reported recent studies. Dysfunctional mitochondria occupy an position cellular metabolic reprogramming, immune microenvironment regulation, programmed cell death. Therefore, targeting may represent new mechanism to overcome therapeutic barriers treatment provides crucial target molecules for further development targeted therapies immunotherapies. The present article summarizes reports links it various death mechanisms, aiming provide basis clinical practice.

Language: Английский

Citations

0